KTH Holding AB has invested in Glycolink, a company developing a sustainable hydrogel technology, to support its transition from research to commercialization.

Information on Glycolink

Glycolink is a pioneering company offering a unique hydrogel based on a technology platform developed at the KTH Royal Institute of Technology. Their innovative approach combines a novel protein that acts as a crosslinker, binding to certain polysaccharides to create a 100% biocompatible and biodegradable hydrogel sourced from renewable resources. The protein is produced recombinantly in their laboratory, while the polysaccharide is cultivated from fungi on low-cost carbon substrates.

This innovative hydrogel shows versatile and tunable properties, comparable to other hydrogels, and can be processed without toxic chemicals, thereby significantly reducing production costs and waste footprints. Glycolink's technology has potential applications across various industries, particularly in cosmetics and life sciences.

Industry Overview in Sweden

Sweden is known for its commitment to innovation and sustainability, particularly in the biotechnology and cosmetics industries. The country's robust research infrastructure, coupled with its focus on sustainability, has fostered a thriving e

View Source

Similar Deals

Industrifonden Cellevate

2024

Seed Stage Biotechnology & Medical Research (NEC) Sweden
Eir Ventures RAPP

2023

Seed Stage Healthcare Facilities & Services (NEC) Sweden
STOAF III SciTech Developeration AB

2023

Seed Stage Medical Devices & Implants Sweden
Flerie Invest Empros Pharma AB

2023

Seed Stage Proprietary & Advanced Pharmaceuticals Sweden
Undisclosed Investors OlsAro

2023

Seed Stage Biotechnology & Medical Research (NEC) Sweden
Eir Ventures Strike Pharma

2023

Seed Stage Proprietary & Advanced Pharmaceuticals Sweden

KTH Holding AB

invested in

Glycolink AB

in 2023

in a Seed Stage deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert